The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
1- 10 quid, some buttons and a packet of crisps.
2- 40 mill
3- 20 mill and most spent on hookers
4- frigging eternity
As you can see spif we are well and truly royally foo.ed- I wouldn't touch this company with a barge pole. Go and invest/trade somewhere else.
Toodle pip
Sad, in regards to 1802- I think some of these points during half yearly investor meet may shed some light on where this new patent maybe going or maybe not- just my opinion.
Half yearly Inv meet-
https://m.youtube.com/watch?v=KJFhOEmaPFw
7.55- Dr Reader reader mentioning Tyk2 and viral bacterial pneumonia, then advising Tyk2/Jak1 has the potential to yield superior efficacy against Tyk2 alone. (It's a biggie all respiratory illness, covid etc.)
12.40- 1801 and 1802 derived from same chemical class, so can push forward with 1802 learning from 1801 experience.
26.15- 1802 translation studies are in progress and done some short term acute tox studies already all of which were fine. Manufacture will be in line with 1801 process so no hanging about when they are ready.
27.20- 1802 will begin clinical trials in patients not healthy subjects.
Australia is built on first-in-human on healthy subjects so may not be in Australia.
And will be quite a different ph1 clinical trial than that envisaged for 1801.
Funny, I don't know what you trying to get at although I'll take a wild guess and say your pointing at the first comment in todays RNS.
Well we mentioned back in Dec 2017 RNS all major market and at that time 1802 to my recollection was not in existence.
As per that RNS-
Patent Grants in Japan and China for Sareum's TYK2 Inhibitors
Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Japanese Patent Office has granted a patent for inventions associated with Sareum's TYK2 Kinase Inhibitor Programme, and that the Chinese Patent Office has issued notification that such a patent will be granted subject to certain formalities being completed.
This patent* describes compounds that inhibit JAK kinase enzyme function, in particular TYK2 kinase. It also describes the use of these compounds in the treatment of disease mediated by these kinase enzymes, including autoimmune diseases such as multiple sclerosis, psoriasis and inflammatory bowel disease.
The granting of the Japanese patent and the imminent granting of the Chinese patent mean that Sareum will have approved patent protection in Japan and China for its TYK2 inhibitor programme. Similar patent protection in Europe was announced on 10 November 2014 and the Company expects that similar patents will be granted in other major markets, including the USA, in due course.
* Japanese Patent no. 6239118, Chinese Patent Application no. 201380080517X
Sareum's CSO, Dr John Reader, commented: "The granting of this patent in Japan and China is a key step in securing the protection of the intellectual property for our TYK2 programme in all major markets and it enhances the value of this programme as we progress discussions with potential licensing partners."
Try and FUD someplace else and it's the last time I'm replying to you as we are now clinical stage and I have mentioned before this is where sea lioning kicks in.
Well add these patents to the list- as mentioned still believe £20 for everything undervalues us.
Someone made the link to China some time ago for picking Aus for 1801 so well done them as looks exactly the case for a target market now.
In regards to 1802 new patent grant- well all I can say is they maybe looking at Lupus- remember 1802 was the compound successfully tested by the US Army in Lupus.
As per the Research update RNS-
These studies were supported by a research grant from the US Department of Defense (DoD) and the report was recently published on the website of the Defense Technical Information Center (https://apps.dtic.mil/sti/citations/AD1087498).
The authors concluded that an approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression and may benefit numerous lupus patients in need of new options. They also noted that the results could influence treatments of other autoimmune diseases such as arthritis and psoriasis.
Specifically, it was reported that treatment with TYK2/JAK1 inhibitor SAR-20351 (now known as SDC-1802) reduces autoantibodies (biological markers of lupus severity) in a spontaneous mouse model of SLE. The data also provided evidence that SAR-20351 inhibits cytokines that play a critical role in lupus, including interferon-alpha, IL-6 and IL-23. The inhibition of IL-23 signalling by SAR-20351 may play a role in the decrease of autoantibodies in the lupus mouse model, as IL-23 signalling drives the differentiation of Th17 cells, which leads to autoantibody production and are pathogenic in lupus.
Many happy returns chaps.
Forgot to add-
As always lets see what comes to pass, we are in clinic so a long way to go and no guarantees. But lre-clins have sold for low billions and we are no longer pre-clin and the further we go to the higher the price.
Also Sareum have already remarked on Tyk2 and we are Tyk2/Jak1 so we belive we are superior-
As per the AGM statement-
'TYK2/JAK1 inhibition has demonstrated benefits in maintaining a healthy immune system and has strong clinical validation in psoriasis and psoriatic arthritis and we believe this asset has great potential. This week we have seen evidence of the continued commercial interest in the TYK2 class following the announcement by Takeda of plans to acquire Nimbus Lakshmi Inc., a unit of Nimbus Therapeutics for an upfront consideration of US$4 billion. We believe this underscores the great potential of this class'.
Not a chance Baton, they didn't side step MHRA to go Aus for 1801 just for s.its and giggles. We are looking at no less than £20 for the lot.
That includes-
- 1801 a 100% owned Tyk2/Jak1 auto-immune compound administered via capsule as once daily treatment. Patented in all major markets and now clinical stage. With Sar mentioning-
'TYK2/JAK1 inhibition has demonstrated benefits in maintaining a healthy immune system and has strong clinical validation in psoriasis and psoriatic arthritis. Psoriasis is an autoimmune dermatological condition affecting more than 60 million adults worldwide, with a market size for potential treatments estimated to be worth more than US$30 billion. Sareum believes that TYK2/JAK1 inhibition offers potential for increased efficacy in psoriasis, compared with existing approved therapies'.
- 1802 (the biggy in most investors eyes) again a 100% owned Tyk2/Jak1 cancer compound likely also once daily capsule as per AGM using 1801 study as testing pad. Twice world-wide patent protected with the last 2 patents for the first time in our history naming target indications-
Euro patent grant-
The patent will come into effect on 4 May 2022.
The patent (EPO Patent no. EP3528806) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat T-cell acute lymphoblastic leukaemia (T-ALL - a cancer of a particular type of white blood cell called a T lymphocyte) and other cancers that are dependent on TYK2 kinase for survival. This programme is in preclinical development".
- And the US patent grant in 2021-
The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase.
And remember as per the investormeet Dr Reader saif it will go straight into hospital patients and some acute tox studies have already been done which were good.
- Chk1 speaks for itself, ph3 ready per website and looking fantastic in combo therapy.
- Aurora Flt3 again speaks for itself- just needs someone to crack formulation issues (Sar could do it I think but need funding).
- And last but not least The SKIL Platform essentially the goose that lays the golden eggs, it has created all of the above so evidentally works and can create more no doubt and for which to date no one has been able to value.
I am sure folk like RMM can draw out proper financial post but even £20 is probably undervaluing it moreover £40+ esp. if we get to ph2 with 1801 with little to no tox and either high or no MTD found so selecting a therapuetically effective dose as then that almost certainly validates 1802 in it's make up and as Dr Reader remarked Ph1b (yes ph1b efficacy, not ph2) will be gamechanging as we will be able to compare against Pfizer and pre-clinically we have shown good safety.
Watch from 38.10 when Dr Parker mentions they have engaged with us- look at Dr Readers body language and glance at him then Clive Birchs look over and thereafter Dr Mitchells nod when he mentions approaches.
Without reading too much into it they probably already have something lined up so as they say just a matter crossing t's and dotting the i's, we know licencing deals esp. when multiple parties are involved can be long drawn out affair.
Not only is it more advanced Cancer Reasearch and namely Dr Workmann have gone out of their way to shout about it in combo therapy. In my opinion I feel a deal is due to be announced soon the silence is deafening since we've had it back and we know that both Sareum and CRT have had multiple approaches about it.
Remember this from the AGM-
https://m.youtube.com/watch?v=1x1_ktQPLik
38:25- Dr Parker advising he has been personally approached about Chk1 as well and CPF. What a comment 'create an orderly cue'.
Oh Funny, forgot to mention gsk also already have chk1 inhibitor at ph2 or ph3 so probably looked at our chk1 and said meh. But don't worry they love p.ssing money away so they may well shelve theirs and go for ours- stranger things have happened.
Funny, just for s.its and giggles as they like p.ssing money away on half bit compounds. You see momo was passed about a bit like a hooker for low millions then eventually sierra sold the lot to gsk for 2bn.
From google meister-
"The drug was initially developed by Cytopia and then YM Biosciences before Gilead acquired YM and momelotinib for $510 million in 2012. But mixed results in one trial and negative data in another led Gilead to give up on momelotinib, sending its rights to Sierra in 2018 for just $3 million upfront".
You all just s.its and giggles and people says scientists and pharma folk have no sense of humour.
🤣
I understand that Potnak for the gamestop thing, it's the other ones going down- like avacta for example who are nearing ph1a at cohort 5 no mtd and the price is pretty much been dragged down lower that it was before a single person was dosed with a chemo drug.
It's very dubious to say the least- we found out spurs/grover on here and then there was that other chap 1 or 2yrs ago who grassed on his hedgefund after being sacked by pulling a list of AIM stocks he was paid to deramp.
MM's, brokers etc. were also culpable during the gamestop fiasco as per this tweet from US Rep. Alexandria Ocasio-Cortez-
We now need to know more about
@RobinhoodApp's decision to block retail investors from purchasing stock while hedge funds are freely able to trade the stock as they see fit.
As a member of the Financial Services Cmte, I’d support a hearing if necessary.
Their repsonse-
"It was not because we wanted to stop people from buying these stocks," Robinhood explained in the post on Saturday. "We did this because the required amount we had to deposit with the clearinghouse was so large—with individual volatile securities accounting for hundreds of millions of dollars in deposit requirements—that we had to take steps to limit buying in those volatile securities to ensure we could comfortably meet our requirements."
The question is was it the truth or did they help out hedgefunds to close shorts so they didn't get ruined- we will never know and it won't be the last time this type thing happens.
Anyhoo, back to Sareum- ph1a still going along nicely I assume and if you didn't know already we're now a clinical stage company.
As Mafuta would say- Love, Hugs and Kisses. 😉
Potnak, there are alot of people who could benefit in driving the price either way.
Here are some examples-
https://pubmed.ncbi.nlm.nih.gov/10736971/
Conclusions: Our results provide indirect evidence that insider trading may be common in the biotechnology industry.
Bashers- https://www.investopedia.com/terms/s/stockbasher.asp
When they get paid to FUD and bring the price down by targeting informed investors-
https://twitter.com/RAH00084/status/1612746376936574979?t=l-yJmr2URFk5XUSOesgVhg&s=08
Unfortunately it is wide spread, one of the most recent was the gamestop one which even US Senate involved-
https://www.google.com/amp/s/www.cnbc.com/amp/2021/01/30/gamestop-reddit-and-robinhood-a-full-recap-of-the-historic-retail-trading-mania-on-wall-street.html
Aah yes, grover woof and his other acc. spurs was it.
I did say bsck in March that once we get closer to and in clinic we start seeing this type of nonsense again and will get worse as the sealioning will start at each cohort. But as I pointed out yesterday it is out of Sareums hands and everything under the command of the safety committee.
Krone, maybe so but that has always been the case to be honest. However, no we are in clinic it should be more frequent but it is out of Sars hand as the safety committee is in charge now as per the first dosing RNS-
Part 2 (multiple ascending dose) is planned to commence after the Safety Review Committee (SRC) has evaluated the available data from at least Cohorts A, B, and C in Part 1.
Dose escalations and move to the cohort etc. is taken out of Sareums hands.
Still uber exciting though as we are in clinic for the first time in our history and all pre-clinical indications point to us aceing ph1a and getting to ph1b efficacy, question is at what dose level will we find MTD and or become toxic or as we are tyk2/jak1 is it even possible to become find mtd or become toxic? So we may end up picking a therapeutically effective dose- Exciting times ahead.
There is a progress and price disconnect here. We have a 100% owned molecule with no tox or mtd and patented in all major markets in clinic.
We have transformed into a clinical stage company and it's probably been a week or so since we first dosed.
Anyone who knows biotech instrincly will tell you there is a disconnect. In my opinion we should be at least £2.50 as we also have chk1 ph3 ready as per the investor pres and website slides and 1802 which has a similar makeup to 1801 but twice world-wide patent protected and we are told will go straight into cancer patients not healthy volunteers like 1801 when it hit ph1.
We got a licencing deal RNS about 3months after Sar advised advised chk1 was going to first dose at Royal Marsden, so lets see what happens with 1801 shall we.
Many happy returns- the see-saw, swings and roundabouts continue, but for those who see value just a matter of patience as always to which most long-termers have become accustomed to.